Source link : https://newshealth.biz/health-news/fda-approves-zongertinib-for-her2-mutated-nsclc/
The FDA has granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.) for certain adults with unresectable or metastatic nonsquamous non-small cell lung cancer (NSCLC). Specifically, the TKI was approved for patients whose tumors harbor HER2 (ERBB2) tyrosine kinase domain-activating mutations as detected by an FDA-approved test and who have received prior systemic therapy, […]
The post FDA Approves Zongertinib for HER2-Mutated NSCLC first appeared on News Health.
—-
Author : News Health
Publish date : 2025-08-08 21:23:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8